Related Experiment Video
Updated: Jan 6, 2026

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
Synergism between ATM and PARP1 Inhibition Involves DNA Damage and Abrogating the G2 DNA Damage Checkpoint
Joyce P Y Mak1, Hoi Tang Ma1, Randy Y C Poon2
1Division of Life Science, Center for Cancer Research, and State Key Laboratory of Molecular Neuroscience, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Abstract:
PARP inhibitors have emerged as effective chemotherapeutic agents for BRCA1/BRCA2-deficient cancers. Another DNA damage response protein, ATM, is also increasingly being recognized as a target for synthetic lethality with PARP inhibitors. As ATM functions in both cell cycle arrest and DNA repair after DNA damage, how cells respond to inhibition of ATM and PARP1 is yet to be defined precisely. We found that loss of ATM function, either in an ATM-deficient background or after treatment with ATM inhibitors (KU-60019 or AZD0156), results in spontaneous DNA damage and an increase in PARylation. When PARP1 is also deleted or inhibited with inhibitors (olaparib or veliparib), the massive increase in DNA damage activates the G2 DNA damage checkpoint kinase cascade involving ATR, CHK1/2, and WEE1. Our data indicated that the role of ATM in DNA repair is critical for the synergism with PARP inhibitors. Bypass of the G2 DNA damage checkpoint in the absence of ATM functions occurs only after a delay. The relative insensitivity of PARP1-deficient cells to PARP inhibitors suggested that other PARP isoforms played a relatively minor role in comparison with PARP1 in synergism with ATMi. As deletion of PARP1 also increased sensitivity to ATM inhibitors, trapping of PARP1 on DNA may not be the only mechanism involved in the synergism between PARP1 and ATM inhibition. Collectively, these studies provide a mechanistic foundation for therapies targeting ATM and PARP1.
Insights
Inhibiting ATM and PARP1 together causes significant DNA damage, activating cell cycle checkpoints. ATM
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Poly (ADP-ribose) polymerase (PARP) inhibitors are effective for BRCA1/BRCA2-deficient cancers.
- ATM protein is a potential target for synthetic lethality with PARP inhibitors.
- The cellular response to combined ATM and PARP1 inhibition requires precise definition.
Purpose of the Study:
- To elucidate the precise cellular response to combined inhibition of ATM and PARP1.
- To investigate the role of ATM in DNA repair for synergism with PARP inhibitors.
- To explore the mechanisms underlying the synergistic effects of ATM and PARP1 inhibition.
Main Methods:
- Utilized ATM-deficient cell lines and ATM inhibitors (KU-60019, AZD0156).
- Employed PARP1 deletion and PARP inhibitors (olaparib, veliparib).
- Analyzed DNA damage, PARylation levels, and G2 DNA damage checkpoint activation (ATR, CHK1/2, WEE1).
Main Results:
- Loss of ATM function leads to spontaneous DNA damage and increased PARylation.
- Combined ATM and PARP1 inhibition activates the G2 DNA damage checkpoint cascade.
- ATM's role in DNA repair is critical for synergism with PARP inhibitors.
- PARP1 inhibition is more critical than other PARP isoforms for this synergism.
- PARP1 deletion enhances sensitivity to ATM inhibitors, suggesting mechanisms beyond PARP1 trapping.
Conclusions:
- ATM inhibition combined with PARP1 inhibition induces significant DNA damage and activates checkpoints.
- ATM's DNA repair function is essential for the synergistic effect with PARP inhibitors.
- The findings provide a mechanistic basis for targeting ATM and PARP1 concurrently in cancer therapy.
More Related Videos
Related Concept Videos
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Restarting Stalled Replication Forks
Negative Regulator Molecules
Long-patch Base Excision Repair
Inhibition of Cdk Activity

